Key Highlights

  • On 30 October 2026, (ASX:C79) was quoted at AUD 7.05, down 3.43%; this article covers FY26 results, operating activity and financial position.
  • FY26 Revenue climbed 33% YoY to AUD 88.1 million, from AUD 66.1 million in FY25.
  • Sample volumes increased 67% YoY to 11.3 million, while 24 new Lease agreements were signed during FY26.

Chrysos Corporation Ltd (ASX:C79) operates in developer and operator of PhotonAssay technology for mineral sample analysis. On 30 October 2026, its shares were quoted at AUD 7.05, down 3.43% for the session. Its FY26 activities bring together financial performance, the movement in operating indicators, the company’s balance-sheet position and the major projects or plans detailed in its reporting. These measures relate to distinct reporting periods and should be read in that context.

Reported performance and financial measures

FY26 revenue climbed 33% YoY to AUD 88.1 million, from AUD 66.1 million in FY25. EBITDA rose 68% YoY to AUD 27.2 million and the EBITDA Margin improved to 31% from 24%. These figures describe different measures and are not interchangeable: revenue represents recognised Business activity, while Earnings measures reflect the expenses and adjustments disclosed for the period. Comparisons against FY25 refer to the prior corresponding year, rather than to the quoted share price.

Profitability and financial position

Sample volumes increased 67% YoY to 11.3 million, while 24 new lease agreements were signed during FY26. Net operating cash inflows totalled AUD 17.9 million; the group reported AUD 25.9 million in cash and AUD 140 million in undrawn debt. The financial measures reported by (ASX:C79) are presented with their own accounting definitions. Where a company uses underlying, normalised or adjusted metrics, those values should remain distinct from statutory profit, and the applicable period should remain explicit when making a comparison.

Operations, contracts and business activity

The company set FY27 revenue guidance of AUD 108–118 million and EBITDA guidance of AUD 35–42 million. Alongside the numerical performance, (ASX:C79) described the operational work associated with its business. Contract delivery, project progress and the timing of recognised income can vary across reporting periods. Accordingly, reported orders, Investment programs and development intentions are separate from revenue already earned in FY26.

Reporting context and stated next steps

For (ASX:C79), the information above combines results for FY26 with operational information and company statements about subsequent activity where those were included in the report. Future targets or guidance are company-stated expectations rather than outcomes already achieved. Differences in reporting dates also matter: amounts presented at 30 June 2026 are not necessarily balances for later dates. The business description and numerical comparisons are kept separate from the historical market quotation.

Key Insights

The FY26 record for Chrysos Corporation Ltd (ASX:C79) encompasses the reported results, business operations and financial position. FY26 revenue climbed 33% YoY to AUD 88.1 million, from AUD 66.1 million in FY25. Sample volumes increased 67% YoY to 11.3 million, while 24 new lease agreements were signed during FY26. The project, contract or development details provide additional context, while guidance and forward plans remain subject to their original stated conditions. The share-price movement on 29 October 2026 is historical trading information and does not by itself establish a cause for the company’s operational or financial performance.